Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioterrorism -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (545)	4/2/2002 10:15:15 AM
From: nigel bates	Read Replies (1) \| Respond to of 891

Cambridge, UK - 2 April 2002 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) notes the recent press comment relating to Aventis' discovery of 70-90 million doses of old smallpox vaccine and Aventis' plans to donate it to the US Government. Acambis confirms that this does not impact in any way the contracts that Acambis has in place with the US Centers for Disease Control and Prevention ("CDC") to deliver 209 million doses of Acambis' new smallpox vaccine. Acambis understands that the old vaccine may be made available to the US Government by Aventis as part of a contingency stockpile in the interim period prior to Acambis delivering its 209 million doses. The US Government remains committed to Acambis under the contracts with the CDC. Acambis' orders for 209 million doses remain in place and are on track to be delivered by the end of 2002.